OGN - Organon & Co. Stock Price, Fair Value and News

18.42USD-0.29 (-1.55%)Market Closed

Market Summary

USD18.42-0.29

Market Closed

-1.55%

OGN Stock Price

View Fullscreen

OGN RSI Chart

OGN Valuation

Market Cap

4.7B

Price/Earnings (Trailing)

4.6

Price/Sales (Trailing)

0.75

EV/EBITDA

9.67

Price/Free Cashflow

8.59

OGN Price/Sales (Trailing)

OGN Profitability

EBT Margin

10.75%

Return on Equity

-1.5K%

Return on Assets

8.48%

Free Cashflow Yield

11.64%

OGN Fundamentals

OGN Revenue

Revenue (TTM)

6.3B

Rev. Growth (Yr)

7.61%

Rev. Growth (Qtr)

5.2%

OGN Earnings

Earnings (TTM)

1.0B

Earnings Growth (Yr)

405.56%

Earnings Growth (Qtr)

841.38%

Breaking Down OGN Revenue

Last 7 days

3.1%

Last 30 days

1.7%

Last 90 days

10.1%

Trailing 12 Months

-22.3%

How does OGN drawdown profile look like?

OGN Financial Health

Current Ratio

1.54

Debt/Equity

-125.01

Debt/Cashflow

0.09

OGN Investor Care

Dividend Yield

6.08%

Dividend/Share (TTM)

1.12

Shares Dilution (1Y)

0.49%

Diluted EPS (TTM)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	6.1B	6.2B	6.2B	6.3B
2022	6.4B	6.4B	6.3B	6.2B
2021	6.3B	6.3B	6.3B	6.3B
2020	7.5B	7.2B	6.8B	6.5B
2019	0	0	0	7.8B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Organon & Co.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2024	walsh matthew m	sold (taxes)	-183,338	18.8	-9,752	chief financial officer
Mar 31, 2024	stahler rachel a	acquired	-	-	10,132	chief information officer
Mar 31, 2024	weaver kirke	acquired	-	-	13,619	gen. counsel & corp. secy.
Mar 31, 2024	nisita vittorio	sold (taxes)	-48,109	18.8	-2,559	head of global business svcs
Mar 31, 2024	dimarco kathryn	sold (taxes)	-82,419	18.8	-4,384	corporate controller
Mar 31, 2024	dimarco kathryn	acquired	-	-	12,797	corporate controller
Mar 31, 2024	weaver kirke	sold (taxes)	-72,981	18.8	-3,882	gen. counsel & corp. secy.
Mar 31, 2024	morrissey joseph t. jr.	acquired	-	-	11,730	head of manufacturing
Mar 31, 2024	ali kevin	sold (taxes)	-628,428	18.8	-33,427	chief executive officer
Mar 31, 2024	nisita vittorio	acquired	-	-	7,469	head of global business svcs

Which funds bought or sold OGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Verity & Verity, LLC	new	-	14,383,000	14,383,000	1.64%
Apr 24, 2024	NBT BANK N A /NY	reduced	-18.57	56.00	1,072	-%
Apr 24, 2024	CENTRAL TRUST Co	reduced	-5.04	6,269	32,600	-%
Apr 24, 2024	Hedges Asset Management LLC	reduced	-19.5	19,961	423,000	0.30%
Apr 24, 2024	Spire Wealth Management	reduced	-4.11	15,883	113,270	-%
Apr 24, 2024	BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC	unchanged	-	136	583	-%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	added	93.77	440,000	728,000	-%
Apr 24, 2024	Essex Financial Services, Inc.	added	8.17	258,669	889,151	0.08%
Apr 24, 2024	Keene & Associates, Inc.	sold off	-100	-1,076,060	-	-%
Apr 24, 2024	Financial Freedom, LLC	added	0.51	883	3,736	-%

Are Funds Buying or Selling OGN?

Are funds buying OGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OGN

No. of Funds

Unveiling Organon & Co.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	11.97%	30,596,708	SC 13G/A
Feb 05, 2024	mawer investment management ltd.	0.00%	0	SC 13G/A
Jan 25, 2024	state street corp	3.72%	9,506,568	SC 13G/A
Jan 23, 2024	blackrock inc.	13.1%	33,523,293	SC 13G/A
Nov 07, 2023	blackrock inc.	12.7%	32,427,810	SC 13G/A
Feb 13, 2023	mawer investment management ltd.	5.39%	13,721,690	SC 13G
Feb 10, 2023	state street corp	5.06%	12,863,077	SC 13G
Feb 09, 2023	vanguard group inc	12.37%	31,471,695	SC 13G/A
Feb 07, 2023	blackrock inc.	6.4%	16,387,716	SC 13G/A
Feb 04, 2022	blackrock inc.	6.7%	16,900,502	SC 13G

Recent SEC filings of Organon & Co.

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 16, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading

Peers (Alternatives to Organon & Co.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	353.7B	85.2B	-5.73%	-9.70%	10.06	4.15	6.46%	95.94%
MRK	330.8B	60.1B	4.06%	15.15%	906.27	5.5	1.40%	-97.49%
AMGN	144.4B	28.2B	-4.38%	12.82%	21.5	5.12	7.09%	2.52%
PFE	142.6B	46.5B	-8.45%	-34.61%	-102.73	3.06	42.59%	-114.62%
GILD	81.3B	27.1B	-9.83%	-22.03%	14.36	3	-0.60%	23.36%
TEVA	14.8B	15.8B	-6.29%	61.39%	-25.76	0.94	6.17%	76.47%
MID-CAP
PRGO	4.2B	4.7B	1.56%	-13.21%	-333.77	0.91	4.58%	90.97%
ALKS	4.1B	1.7B	-8.63%	-13.78%	11.49	2.46	49.61%	324.78%
BHC	3.1B	8.8B	-12.58%	22.10%	-5.32	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-5.53%	6.97%	14.27	3.05	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-24.24%	-19.72%	-3.85	1.82	24.65%	80.36%
TXMD	21.6M	1.3M	-16.89%	-47.03%	-2.1	16.56	-98.14%	-109.18%
ACRX	18.8M	-	-0.89%	64.15%	-1.02	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	21.21%	-93.94%	-0.19	0.14	80.00%	43.08%
ACOR	683.2K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

Organon & Co. News

Latest updates

Organon & Co. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																	(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	5.2%	1,598	1,519	1,608	1,538	1,485	1,537	1,585	1,567	1,603	1,600	1,595	1,506	1,613	1,613	1,526	1,780	-
S&GA Expenses	-12.8%	469	538	451	435	470	440	423	371	482	388	416	382	434	321	284	317	-
R&D Expenses	-	-	-	-	-	-	-	-	96.00	-76.50	111	10.00	67.00	2.00	54.00	51.00	45.00	-
EBITDA Margin	-1.0%	0.21*	0.21*	0.24*	0.24*	0.27*	0.28*	0.29*	0.31*	0.30*	0.30*	0.34*	-	-	-	-	-	-
Interest Expenses	-3.7%	129	134	132	132	119	108	98.00	97.00	98.00	98.00	62.00	-	-	-	-	-	-
Income Taxes	-2109.1%	-442	22.00	12.00	58.00	3.00	55.00	53.00	94.00	34.00	66.00	6.00	72.00	149	121	116	110	-
Earnings Before Taxes	30.0%	104	80.00	254	235	111	282	287	442	236	389	437	467	525	681	702	844	-
EBT Margin	-2.8%	0.11*	0.11*	0.14*	0.15*	0.18*	0.20*	0.21*	0.24*	0.24*	0.29*	0.33*	-	-	-	-	-	-
Net Income	841.4%	546	58.00	242	177	108	227	234	348	202	323	427	399	368	547	542	703	-
Net Income Margin	71.7%	0.16*	0.10*	0.12*	0.12*	0.15*	0.16*	0.17*	0.20*	0.21*	0.24*	0.28*	-	-	-	-	-	-
Free Cashflow	54.4%	318	206	-44.00	68.00	204	262	106	90.00	-12.00	332	386	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	9.5%	12,058	11,012	10,979	10,763	10,955	10,437	10,614	10,597	10,681	11,335	10,908	9,642	10,109
Current Assets	11.3%	4,508	4,050	3,958	3,780	3,931	3,592	3,774	3,719	3,760	4,329	3,911	2,977	3,567
Cash Equivalents	67.4%	693	414	326	459	706	499	545	694	737	1,008	730	141	12.00
Inventory	10.9%	1,315	1,186	1,199	1,121	1,003	879	950	946	915	918	871	924	913
Net PPE	7.9%	1,183	1,096	1,110	1,055	1,018	906	952	970	973	967	976	986	984
Goodwill	0%	4,603	4,603	4,603	4,603	4,603	4,603	4,603	4,603	4,603	4,603	4,603	4,603	4,603
Liabilities	4.5%	12,128	11,601	11,534	-	11,847	-	-	-	-	-	-	-	-
Current Liabilities	17.1%	2,918	2,491	2,387	2,346	2,512	2,328	2,396	2,306	2,597	3,129	2,975	2,875	2,673
Long Term Debt	1.2%	8,751	8,646	8,722	8,703	8,905	8,691	8,884	9,085	9,125	9,259	9,309	-	-
LT Debt, Current	12.5%	9.00	8.00	8.00	8.00	8.00	8.00	9.00	9.00	9.00	39.00	39.00	-	-
LT Debt, Non Current	1.2%	8,751	8,646	8,722	8,703	8,905	8,691	8,884	9,085	9,125	9,259	9,309	-	-
Shareholder's Equity	-Infinity%	-70.00	-	-	-	-892	-	-	-	-1,508	-	-	4,722	5,486
Retained Earnings	2868.8%	443	-16.00	-25.00	-206	-331	-383	-551	-724	-998	-1,128	-1,473	-	-
Additional Paid-In Capital	-	25.00	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.0%	256	256	256	254	254	254	254	254	254	254	254	254	-
Float	-	-	-	5,300	-	-	-	8,600	-	-	-	7,670	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																	(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	52.1%	397	261	27.00	114	267	317	151	123	47.00	368	445	1,300	484	320	733	747	-
Share Based Compensation	0%	27.00	27.00	25.00	22.00	23.00	18.00	19.00	15.00	15.00	15.00	18.00	11.00	8.00	11.00	11.00	10.00	-
Cashflow From Investing	-47.3%	-81.00	-55.00	-70.00	-54.00	-61.00	-213	-83.00	-63.00	-133	-61.00	-249	-38.00	-119	-45.00	-47.00	-39.00	-
Cashflow From Financing	1.3%	-77.00	-78.00	-88.00	-326	-82.00	-77.00	-183	-91.00	-187	-18.00	345	-1,117	-353	-275	-686	-708	-
Dividend Payments	-1.4%	73.00	74.00	74.00	73.00	73.00	74.00	72.00	71.00	71.00	74.00	-	-	-	-	-	-	-

OGN Income Statement

2023-12-31

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenues	$ 6,263	$ 6,174	$ 6,304
Costs, Expenses and Other
Cost of sales	2,515	2,294	2,382
Selling, general and administrative	1,893	1,704	1,668
Research and development	528	471	339
Acquired in-process research and development and milestones	8	107	104
Restructuring costs	62	28	3
Interest expense	527	422	258
Exchange losses	42	11	4
Other expense, net	15	15	17
Total, costs expenses and other	5,590	5,052	4,775
Income Before Income Taxes	673	1,122	1,529
Taxes on income	(350)	205	178
Net Income From Continuing Operations	1,023	917	1,351
Loss From Discontinued Operations - Net of Tax	0	0	0
Net Income	$ 1,023	$ 917	$ 1,351
Earnings per Share - Basic:
Continuing operations (in dollars per share)	$ 4.01	$ 3.61	$ 5.33
Discontinued operations (in dollars per share)	0	0	0
Net Earnings per Share - Basic (in dollars per share)	4.01	3.61	5.33
Earnings per Share - Diluted:
Continuing operations (in dollars per share)	3.99	3.59	5.31
Discontinued operations (in dollars per share)	0	0	0
Net Earnings per Share - Diluted (in dollars per share)	$ 3.99	$ 3.59	$ 5.31
Weighted Average Shares Outstanding:
Basic (in shares)	255,239	254,082	253,538
Diluted (in shares)	256,270	255,169	254,193

OGN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 693	$ 706
Accounts receivable (net of allowance for doubtful accounts of $9 in 2023 and $9 in 2022)	1,744	1,475
Inventories (excludes inventories of $110 in 2023 and $148 in 2022 classified in Other assets)	1,315	1,003
Other current assets	756	747
Total Current Assets	4,508	3,931
Property, plant and equipment, net	1,183	1,018
Goodwill	4,603	4,603
Intangibles, net	533	649
Other assets	1,231	754
Total Assets	12,058	10,955
Current Liabilities:
Current portion of long-term debt	9	8
Trade accounts payable	1,314	1,132
Accrued and other current liabilities	1,389	1,188
Income taxes payable	206	184
Total Current Liabilities	2,918	2,512
Long-term debt	8,751	8,905
Deferred income taxes	47	19
Other noncurrent liabilities	412	411
Total Liabilities	12,128	11,847
Contingencies (Note 20)
Organon & Co. Stockholders' Deficit:
Common stock, $0.01 par value Authorized - 500,000 Issued and outstanding - 255,626 in 2023 and 254,370 in 2022	3	3
Additional paid-in capital	25	0
Retained earnings and accumulated (deficit)	443	(331)
Accumulated other comprehensive loss	(541)	(564)
Total Stockholders' Deficit	(70)	(892)
Total Liabilities and Stockholders' Deficit	$ 12,058	$ 10,955

About Organon & Co.

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

CEO	Mr. Kevin Ali
WEBSITE	organon.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	10000

Organon & Co. Frequently Asked Questions

What is the ticker symbol for Organon & Co.? What does OGN stand for in stocks?

OGN is the stock ticker symbol of Organon & Co.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Organon & Co. (OGN)?

As of Thu Apr 25 2024, market cap of Organon & Co. is 4.71 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OGN stock?

You can check OGN's fair value in chart for subscribers.

What is the fair value of OGN stock?

You can check OGN's fair value in chart for subscribers. The fair value of Organon & Co. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Organon & Co. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Organon & Co. a good stock to buy?

The fair value guage provides a quick view whether OGN is over valued or under valued. Whether Organon & Co. is cheap or expensive depends on the assumptions which impact Organon & Co.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OGN.

What is Organon & Co.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, OGN's PE ratio (Price to Earnings) is 4.6 and Price to Sales (PS) ratio is 0.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OGN PE ratio will change depending on the future growth rate expectations of investors.